Gland Pharma (NSE:GLAND) Change In Payables And Accrued Expense : ₹0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma Change In Payables And Accrued Expense?

Gland Pharma's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was ₹0 Mil. It means Gland Pharma's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Mar. 2024 .

Gland Pharma's Change In Payables And Accrued Expense for the fiscal year that ended in Mar. 2024 was ₹0 Mil. It means Gland Pharma's Accounts Payable & Accrued Expense stayed the same from Mar. 2023 to Mar. 2024 .

Gland Pharma Change In Payables And Accrued Expense Historical Data

The historical data trend for Gland Pharma's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma Change In Payables And Accrued Expense Chart

Gland Pharma Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Gland Pharma Quarterly Data
	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Gland Pharma Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

Gland Pharma Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Gland Pharma's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Gland Pharma (NSE:GLAND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

543245:India

Address

Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307

Website

https://www.glandpharma.com

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma (NSE:GLAND) Headlines

No Headlines